Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: Two sides of the same coin

Autoimmunity Reviews

Volumn 9, Issue 11, 2010, Pages 716-720

  Conti, Fabrizio ^a   Perricone, Carlo ^a   Ceccarelli, Fulvia ^a   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

EXPLORER; Off label; Rituximab; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID;

ARTHRITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; EDITORIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; OFF LABEL DRUG USE; REMISSION; SKIN MANIFESTATION; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CONTROLLED CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 77956181648     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.07.013     Document Type: Editorial

References (29)

1. Clark J., Bourne T., Salaman M.R., Seifert M.H., Isenberg D.A. B lymphocyte hyperactivity in families of patients with systemic lupus erythematosus. J Autoimmun 1996, 9:59-65.
2. Korganow A.S., Knapp A.M., Nehme-Schuster H., Soulas-Sprauel P., Poindron V., Pasquali J.L., Martin T. Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression. J Autoimmun 2010, 34:426-434.
3. Jenks S.A., Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 2009, 8:209-213.
4. Perosa F., Favoino E., Caragnano M.A., Prete M., Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005, 4:526-531.
5. García-Carrasco M., Jiménez-Hernández M., Escárcega R.O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., Zamudio-Huerta L., López-Colombo A., Cervera R. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2009, 8:343-348.
6. De Vita S., Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 2006, 5:443-448.
7. Caporali R., Caprioli M., Bobbio-Pallavicini F., Bugatti S., Montecucco C. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009, 8:591-594.
8. Martinez-Gamboa L., Brezinschek H.P., Burmester G.R., Dörner T. Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev 2006, 5:437-442.
9. Bugatti S., Codullo V., Caporali R., Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 2007, 7:137-142.
10. Thatayatikom A., White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006, 5:18-24.
11. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589.
12. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513.
13. Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982.
14. Gillis J.Z., Dall'era M., Gross A., Yazdany J., Davis J. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 2007, 57:538-542.
15. Gunnarsson I., Sundelin B., Jónsdóttir T., Jacobson S.H., Henriksson E.W., van Vollenhoven R.F. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007, 56:1263-1272.
16. Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007, 66:470-475.
17. Tanaka Y., Yamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007, 17:191-197.
18. Vigna-Perez M., Hernández-Castro B., Paredes-Saharopulos O., Portales-Pérez D., Baranda L., Abud-Mendoza C., et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006, 8:R83.
19. Lindholm C., Börjesson-Asp K., Zendjanchi K., Sundqvist A.C., Tarkowski A., Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008, 35:826-833.
20. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., Isenberg D.A. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61:482-487.
21. Lateef A., Lahiri M., Teng G.G., Vasoo S. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus 2010, 29:765-770.
22. Garcia-Carrasco M., Mendoza-Pinto C., Sandoval-Cruz M., Soto-Vega E., Beltran-Castillo A., Jimenez-Hernandez M., et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2010, 19:213-219.
23. Symmons D.P., Coppock J.S., Bacon P.A., Bresnihan B., Isenberg D.A., Maddison P., McHugh N., Snaith M.L., Zoma A.S. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988, 69:927-937.
24. Ramos-Casals M., Soto M.J., Cuadrado M.J., Khamashta M.A. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009, 18:767-776.
25. Terrier B., Amoura Z., Ravaud P., et al. For the Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AIR registry. Arthritis Rheum 2010, 62:2458-2466. doi:10.1002/art.27541.
26. Gladman D.D., Ibañez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.
27. Mosca M., Bencivelli W., Vitali C., Carrai P., Neri R., Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000, 9:445-450.
28. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., Utset T.O., Gordon C., Isenberg D.A., Hsieh H.J., Zhang D., Brunetta P.G. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
29. Gordon C., Sutcliffe N., Skan J., Stoll T., Isenberg D.A. Definition and treatment of lupus flares measured by the BILAG index. Rheumatol (Oxford). 2003, 42:1372-1379.